Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 April 2004, Vol. 103, No. 8, pp. 3175-3184.
Prepublished online as a Blood First Edition Paper on December 18, 2003; DOI 10.1182/blood-2003-06-2151.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2003-06-2151v1
103/8/3175    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bharti, A. C.
Right arrow Articles by Aggarwal, B. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bharti, A. C.
Right arrow Articles by Aggarwal, B. B.
Related Collections
Right arrow Neoplasia
Right arrow Apoptosis
Right arrow Cell Adhesion and Motility
Right arrow Signal Transduction
Right arrow Clinical Trials and Observations
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

Nuclear factor–{kappa}B and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis

Alok C. Bharti, Shishir Shishodia, James M. Reuben, Donna Weber, Raymond Alexanian, Saroj Raj-Vadhan, Zeev Estrov, Moshe Talpaz, and Bharat B. Aggarwal

From the Departments of Bioimmunotherapy, Hematopathology, and Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston.

Chemoresistance is a major problem in the treatment of patients with multiple myeloma (MM). Because of the central role of the nuclear transcription factors nuclear factor–{kappa}B (NF-{kappa}B) and signal transducer and activator of transcription 3 (STAT3) in chemoresistance, cell survival, and proliferation, we investigated whether MM cells derived from patients express activated NF-{kappa}B and STAT3 and if their suppression induces apoptosis. We assayed CD138+ cells from the bone marrow of 22 MM patients and checked for the activated forms of NF-{kappa}B and STAT3 by immunocytochemistry. We found that MM cells from all the patients expressed the activated forms of NF-{kappa}B and STAT3 but to a variable degree (NF-{kappa}B: low, 3 of 22; moderate, 5 of 22; or high, 14 of 22; STAT3: none, 1 of 22; low, 3 of 22; moderate, 5 of 22; or high, 14 of 22). Constitutive activation of NF-{kappa}B was in some cases also independently confirmed by electrophoretic mobility gel shift assay. In contrast to MM patients, activated forms of NF-{kappa}B and STAT3 were absent in cells from healthy individuals. Suppression of NF-{kappa}B and STAT3 activation in MM cells by ex vivo treatment with curcumin (diferuloylmethane) resulted in a decrease in adhesion to bone marrow stromal cells, cytokine secretion, and in the viability of cells. When compared with curcumin, dexamethasone was less effective in suppression of NF-{kappa}B activation and induction of apoptosis in myeloma cells. Overall, our results indicate that fresh cells from MM patients express constitutively active NF-{kappa}B and STAT3, and suppression of these transcription factors inhibits the survival of the cells. (Blood. 2004;103:3175-3184)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
S. V. Rajkumar
Prevention of Progression in Monoclonal Gammopathy of Undetermined Significance
Clin. Cancer Res., September 15, 2009; 15(18): 5606 - 5608.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Wang, G. Tricot, L. Shi, W. Xiong, Z. Zeng, H. Xu, M. Zangari, B. Barlogie, J. D. Shaughnessy Jr, and F. Zhan
RAR{alpha}2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma
Blood, July 16, 2009; 114(3): 600 - 607.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
B. Sung, A. B. Kunnumakkara, G. Sethi, P. Anand, S. Guha, and B. B. Aggarwal
Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model
Mol. Cancer Ther., April 1, 2009; 8(4): 959 - 970.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. Sung, A. Murakami, B. O. Oyajobi, and B. B. Aggarwal
Zerumbone Abolishes RANKL-Induced NF-{kappa}B Activation, Inhibits Osteoclastogenesis, and Suppresses Human Breast Cancer-Induced Bone Loss in Athymic Nude Mice
Cancer Res., February 15, 2009; 69(4): 1477 - 1484.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. B. Aggarwal, R.V. Vijayalekshmi, and B. Sung
Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe
Clin. Cancer Res., January 15, 2009; 15(2): 425 - 430.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
R. Burger, S. Le Gouill, Y.-T. Tai, R. Shringarpure, P. Tassone, P. Neri, K. Podar, L. Catley, T. Hideshima, D. Chauhan, et al.
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo
Mol. Cancer Ther., January 1, 2009; 8(1): 26 - 35.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. B. Kunnumakkara, H. Ichikawa, P. Anand, C. J. Mohankumar, P. S. Hema, M. S. Nair, and B. B. Aggarwal
Coronarin D, a labdane diterpene, inhibits both constitutive and inducible nuclear factor-{kappa}B pathway activation, leading to potentiation of apoptosis, inhibition of invasion, and suppression of osteoclastogenesis
Mol. Cancer Ther., October 1, 2008; 7(10): 3306 - 3317.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. R. Hussain, M. Ahmed, N. A. Al-Jomah, A. S. Khan, P. Manogaran, M. Sultana, J. Abubaker, L. C. Platanias, K. S. Al-Kuraya, and S. Uddin
Curcumin suppresses constitutive activation of nuclear factor-{kappa}B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines
Mol. Cancer Ther., October 1, 2008; 7(10): 3318 - 3329.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Sharma and A. Lichtenstein
Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors
Blood, August 15, 2008; 112(4): 1338 - 1345.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
S. Markovina, N. S. Callander, S. L. O'Connor, J. Kim, J. E. Werndli, M. Raschko, C. P. Leith, B. S. Kahl, K. Kim, and S. Miyamoto
Bortezomib-Resistant Nuclear Factor-{kappa}B Activity in Multiple Myeloma Cells
Mol. Cancer Res., August 1, 2008; 6(8): 1356 - 1364.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Narasimhan and S. Ammanamanchi
Curcumin Blocks RON Tyrosine Kinase-Mediated Invasion of Breast Carcinoma Cells
Cancer Res., July 1, 2008; 68(13): 5185 - 5192.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
G. Sethi, B. Sung, and B. B. Aggarwal
Nuclear Factor-{kappa}B Activation: From Bench to Bedside
Experimental Biology and Medicine, January 1, 2008; 233(1): 21 - 31.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
B. Sung, M. K. Pandey, Y. Nakajima, H. Nishida, T. Konishi, M. M. Chaturvedi, and B. B. Aggarwal
Identification of a novel blocker of I{kappa}B{alpha} kinase activation that enhances apoptosis and inhibits proliferation and invasion by suppressing nuclear factor-{kappa}B
Mol. Cancer Ther., January 1, 2008; 7(1): 191 - 201.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. K. Pandey, B. Sung, K. S. Ahn, A. B. Kunnumakkara, M. M. Chaturvedi, and B. B. Aggarwal
Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-{kappa}B signaling pathway
Blood, November 15, 2007; 110(10): 3517 - 3525.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
D. Cilloni, G. Martinelli, F. Messa, M. Baccarani, and G. Saglio
Nuclear factor {kappa}B as a target for new drug development in myeloid malignancies
Haematologica, September 1, 2007; 92(9): 1224 - 1229.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. K. Pandey, S. K. Sandur, B. Sung, G. Sethi, A. B. Kunnumakkara, and B. B. Aggarwal
Butein, a Tetrahydroxychalcone, Inhibits Nuclear Factor (NF)-{kappa}B and NF-{kappa}B-regulated Gene Expression through Direct Inhibition of I{kappa}B{alpha} Kinase beta on Cysteine 179 Residue
J. Biol. Chem., June 15, 2007; 282(24): 17340 - 17350.
[Abstract] [Full Text] [PDF]


Home page
Evid Based Complement Alternat MedHome page
S. Salvioli, E. Sikora, E. L. Cooper, and C. Franceschi
Curcumin in Cell Death Processes: A Challenge for CAM of Age-Related Pathologies
Evid. Based Complement. Altern. Med., June 1, 2007; 4(2): 181 - 190.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Bhardwaj, G. Sethi, S. Vadhan-Raj,, C. Bueso-Ramos, Y. Takada, U. Gaur, A. S. Nair, S. Shishodia, and B. B. Aggarwal
Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-{kappa}B-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells
Blood, March 15, 2007; 109(6): 2293 - 2302.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. Feng, G. Anderson, G. Xiao, G. Elliott, L. Leoni, M. Y. Mapara, G. D. Roodman, and S. Lentzsch
SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-{kappa}B activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth
Blood, March 1, 2007; 109(5): 2130 - 2138.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Gururajan, T. Dasu, S. Shahidain, C. D. Jennings, D. A. Robertson, V. M. Rangnekar, and S. Bondada
Spleen Tyrosine Kinase (Syk), a Novel Target of Curcumin, Is Required for B Lymphoma Growth
J. Immunol., January 1, 2007; 178(1): 111 - 121.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Pedranzini, T. Dechow, M. Berishaj, R. Comenzo, P. Zhou, J. Azare, W. Bornmann, and J. Bromberg
Pyridone 6, A Pan-Janus-Activated Kinase Inhibitor, Induces Growth Inhibition of Multiple Myeloma Cells
Cancer Res., October 1, 2006; 66(19): 9714 - 9721.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Ichikawa, M. S. Nair, Y. Takada, D.B. A. Sheeja, M.A. S. Kumar, O. V. Oommen, and B. B. Aggarwal
Isodeoxyelephantopin, a Novel Sesquiterpene Lactone, Potentiates Apoptosis, Inhibits Invasion, and Abolishes Osteoclastogenesis through Suppression of Nuclear Factor-{kappa}B (NF-{kappa}B) Activation and NF-{kappa}B-Regulated Gene Expression.
Clin. Cancer Res., October 1, 2006; 12(19): 5910 - 5918.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
F. A. Piazza, M. Ruzzene, C. Gurrieri, B. Montini, L. Bonanni, G. Chioetto, G. Di Maira, F. Barbon, A. Cabrelle, R. Zambello, et al.
Multiple myeloma cell survival relies on high activity of protein kinase CK2
Blood, September 1, 2006; 108(5): 1698 - 1707.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H. Ichikawa, Y. Takada, S. Shishodia, B. Jayaprakasam, M. G. Nair, and B. B. Aggarwal
Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-{kappa}B (NF-{kappa}B) activation and NF-{kappa}B-regulated gene expression.
Mol. Cancer Ther., June 1, 2006; 5(6): 1434 - 1445.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Shishodia, G. Sethi, M. Konopleva, M. Andreeff, and B. B. Aggarwal
A Synthetic Triterpenoid, CDDO-Me, Inhibits I{kappa}B{alpha} Kinase and Enhances Apoptosis Induced by TNF and Chemotherapeutic Agents through Down-Regulation of Expression of Nuclear Factor {kappa}B-Regulated Gene Products in Human Leukemic Cells
Clin. Cancer Res., March 15, 2006; 12(6): 1828 - 1838.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Braun, G. Carvalho, A. Coquelle, M.-C. Vozenin, P. Lepelley, F. Hirsch, J.-J. Kiladjian, V. Ribrag, P. Fenaux, and G. Kroemer
NF-{kappa}B constitutes a potential therapeutic target in high-risk myelodysplastic syndrome
Blood, February 1, 2006; 107(3): 1156 - 1165.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Ichikawa and B. B. Aggarwal
Guggulsterone Inhibits Osteoclastogenesis Induced by Receptor Activator of Nuclear Factor-{kappa}B Ligand and by Tumor Cells by Suppressing Nuclear Factor-{kappa}B Activation
Clin. Cancer Res., January 15, 2006; 12(2): 662 - 668.
[Abstract] [Full Text] [PDF]


Home page
JPEN J Parenter Enteral NutrHome page
S. Bengmark
Curcumin, An Atoxic Antioxidant and Natural NF{kappa}B, Cyclooxygenase-2, Lipooxygenase, and Inducible Nitric Oxide Synthase Inhibitor: A Shield Against Acute and Chronic Diseases
JPEN J Parenter Enteral Nutr, January 1, 2006; 30(1): 45 - 51.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Gazitt
Not all that glitters is gold
Blood, December 15, 2005; 106(13): 4025 - 4026.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Buzzeo, S. Enkemann, R. Nimmanapalli, M. Alsina, M. G. Lichtenheld, W. S. Dalton, and D. M. Beaupre
Characterization of a R115777-Resistant Human Multiple Myeloma Cell Line with Cross-Resistance to PS-341
Clin. Cancer Res., August 15, 2005; 11(16): 6057 - 6064.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
N. Raje, S. Kumar, T. Hideshima, A. Roccaro, K. Ishitsuka, H. Yasui, N. Shiraishi, D. Chauhan, N. C. Munshi, S. R. Green, et al.
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma
Blood, August 1, 2005; 106(3): 1042 - 1047.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Takada, M. Andreeff, and B. B. Aggarwal
Indole-3-carbinol suppresses NF-{kappa}B and I{kappa}B{alpha} kinase activation, causing inhibition of expression of NF-{kappa}B-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells
Blood, July 15, 2005; 106(2): 641 - 649.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. Ichikawa, Y. Takada, A. Murakami, and B. B. Aggarwal
Identification of a Novel Blocker of I{kappa}B{alpha} Kinase That Enhances Cellular Apoptosis and Inhibits Cellular Invasion through Suppression of NF-{kappa}B-Regulated Gene Products
J. Immunol., June 1, 2005; 174(11): 7383 - 7392.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
L. Zhu, G. Somlo, B. Zhou, J. Shao, V. Bedell, M. L. Slovak, X. Liu, J. Luo, and Y. Yen
Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma
Mol. Cancer Ther., May 1, 2005; 4(5): 787 - 798.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. Ikezoe, Y. Yang, K. Bandobashi, T. Saito, S. Takemoto, H. Machida, K. Togitani, H. P. Koeffler, and H. Taguchi
Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-{kappa}B signal pathways
Mol. Cancer Ther., April 1, 2005; 4(4): 578 - 586.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Sanda, S. Iida, H. Ogura, K. Asamitsu, T. Murata, K. B. Bacon, R. Ueda, and T. Okamoto
Growth Inhibition of Multiple Myeloma Cells by a Novel I{kappa}B Kinase Inhibitor
Clin. Cancer Res., March 1, 2005; 11(5): 1974 - 1982.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
S. O'Connor, S. Shumway, and S. Miyamoto
Inhibition of I{kappa}B{alpha} Nuclear Export as an Approach to Abrogate Nuclear Factor-{kappa}B-Dependent Cancer Cell Survival
Mol. Cancer Res., January 1, 2005; 3(1): 42 - 49.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020